US EditionDrugmakers Are Pouring Billions of Dollars Into New US Manufacturing. It Still Won’t Achieve All of Trump’s Tariff Goals
UNITED STATES, AUG 2 – Pharmaceutical companies plan over $250 billion in US manufacturing investments amid tariff threats, but experts say these moves may not reduce drug costs or reliance on imports.
- President Donald Trump started promising tariffs on pharmaceutical imports while drugmakers committed massive investments to expand US manufacturing.
- These commitments mostly stem from tariffs threat and national security concerns, but some investments began before Trump took office and analysts warn some may not materialize.
- Major companies like Johnson & Johnson, AstraZeneca, and Eli Lilly pledged $55 billion, $50 billion, and $27 billion respectively, pushing total planned investments beyond $250 billion.
- Industry leader John Murphy III expressed doubt that the market could sustain new production if it were established, while Erin Fox emphasized that imposing blanket tariffs is unlikely to increase domestic manufacturing of these medications.
- Despite investment surges, experts warn the expansions may not reduce drug costs or US reliance on foreign sources, given low reimbursements and high production costs domestically.
Insights by Ground AI
Does this summary seem wrong?
11 Articles
11 Articles
Drugmakers are pouring billions of dollars into new US manufacturing. It still won’t achieve all of Trump’s tariff goals
Ever since President Donald Trump started promising to slap tariffs on pharmaceutical imports, drugmakers have unveiled a flurry of commitments to build or expand US manufacturing operations in the coming years.
·Atlanta, United States
Read Full ArticleCoverage Details
Total News Sources11
Leaning Left1Leaning Right1Center9Last UpdatedBias Distribution82% Center
Bias Distribution
- 82% of the sources are Center
82% Center
C 82%
Factuality
To view factuality data please Upgrade to Premium
